ZFP Therapeutic

Type: Product

Name: ZFP Therapeutic

First reported 8 hours ago - Updated 22 mins ago - 2 reports

Sangamo BioSciences Receives $6.4M Strategic Partnership Award from CIRM

Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia ... [Published Benzinga.com - 8 hours ago]

Entities: Sangamo BioSciences Inc, Stem Cell, Hematopoietic

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T

Unprecedented Immune Reconstitution Drives HIV Viral Reservoir Depletion Encouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 TrialsSEE SLIDES BELOWRICHMOND, Calif., May 15, 2013 /PRNewswire/ -- Sangamo ... [Published National AIDS Treatment Advocacy Project - May 23 2013]

Entities: HIV/AIDS, T-cells, Cytoxan, Infusion, ZFP Therapeutic

First reported May 21 2013 - Updated May 21 2013 - 1 reports

OSI Systems Inc

Stocks in Focus (OSI Systems, Empresas ICA SA, Sangamo Biosciences, Theravance Inc)

Austin, TX -- (SBWIRE) -- 05/21/2013 -- Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-OSI Systems, ... [Published SBWire - May 21 2013]

Entities: Sangamo BioSciences Inc, OSI Systems Inc, Theravance Inc, Empresas ICA SAB de CV

First reported May 20 2013 - Updated May 20 2013 - 2 reports

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For..

RICHMOND, Calif.(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) "Our IVPRP provides a potentially curative therapeutic solution for hemophilia A – a monogenic disease caused by the absence of the coagulation protein, Factor VIII," said ... [Published ADVFN UK - May 20 2013]

Entities: Sangamo BioSciences Inc, Factor VIII, Therapeutics, ZFP Therapeutic

First reported May 15 2013 - Updated May 16 2013 - 5 reports

Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs

An experimental gene therapy technique that modifies CD4 T-cells to protect them from viral entry produced lasting CD4 cell increases with a single infusion, as well as reduction in proviral DNA reservoirs and decreased viral load in 2 patients who underwent ... [Published HIV and Hepatitis.com - May 15 2013]

Entities: HIV/AIDS, T-cells, Infusion, Zinc Finger

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Affymax Inc

Healthcare Review: Sangamo Biosciences, MannKind Corporation, Orexigen Therapeutics, Bristol Myers Squibb, Affymax

U.S. stocks climbed to record highs Wednesday as weak data reinforced an expectation that stimulative central bank policies would continue, while evidence that Europe was stuck in recession pushed the euro to a six-week low against the dollar. U.S. producer ... [Published BioMedReports - May 15 2013]

Entities: Affymax Inc, Sangamo BioSciences Inc, Orexigen Therapeutics Inc, MannKind Corp

First reported May 08 2013 - Updated May 09 2013 - 3 reports

Sangamo BioSciences Inc

Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at ... [Published Individual.com - May 09 2013]

Entities: Sangamo BioSciences Inc, ZFP Therapeutic, Bank of America Merrill Lynch

First reported May 01 2013 - Updated May 01 2013 - 2 reports

SANGAMO BIOSCIENCES, INC.: Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast

/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2013 financial results on Wednesday, May 8, 2013, after the market closes. The press release will be followed by a conference call ... [Published 4 Traders - May 01 2013]

Entities: Sangamo BioSciences Inc, ZFP Therapeutic, Hemophilia

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference

/PRNewswire/ --$ Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic ® development programs and an overview of the company's business ... [Published Barchart - Apr 24 2013]

Entities: Sangamo BioSciences Inc, Healthcare Conference, ZFP Therapeutic

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Sangamo BioSciences, Inc. (SGMO) - Financial and Strategic SWOT Analysis Review - new company profile report

Sangamo BioSciences, Inc. (Sangamo) is a clinical stage biopharmaceutical company. It undertakes the research and development (R&D) of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The company carries out research, development ... [Published TransWorldNews - Apr 22 2013]

Entities: Sangamo BioSciences Inc, SWOT Analysis, Therapeutics, Corporate Strategy, ZFP Therapeutic

Quotes

"Sangamo's powerful and precise ZFN-genome editing technology enables modification of a patient's own stem cells and potentially provides a safer approach to current therapies for hemoglobinopathies such as beta-thalassemia and sickle cell disease" said Mark Walters, M D , Director of Blood and Marrow Transplantation at Children's Hospital & Research Center Oakland and a member of the clinical team...

Sangamo BioSciences Receives $6.4M Strategic Partnership Award from CIRM [Published Benzinga.com - 8 hours ago]

"CIRM support for this program is yet another major validation of our ZFP Therapeutics platform," said Edward Lanphier, Sangamo's president and CEO. "The award will assist the development of our stem cell-based ZFP Therapeutic for the potential cure of thalassemia. Importantly, this same approach can be directly applied to related hemoglobinopathies such as sickle cell disease. We look forward to working with a team of world-renowned experts in this field, including the team at Children's Hospital & Research Center Oakland and our colleagues at CIRM, to bring this treatment through IND application and into a Phase 1 clinical trial."

Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute f ... [Published ADVFN India - 8 hours ago]

...from Sangamo's PhasePhase 1 clinical trial SB-728-902 Cohorts 1-3 in a second presentation at 2:15 pm MT, on Thursday, May 16, 2013, Abst.#: 58 "Long Term CD4 Reconstitution in HIV Subjects Receiving ZFN CCR5 Modified CD4 T-Cells (SB-728-T) May Be Attributed to the Sustained Durability of the Central Memory T-Cell Subset."

Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected ... [Published National AIDS Treatment Advocacy Project - May 23 2013]

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) "Our IVPRP provides a potentially curative therapeutic solution for hemophilia A – a monogenic disease caused by the absence of the coagulation protein, Factor VIII" said Philip Gregory

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development O ... [Published ADVFN UK - May 20 2013]

More Content

sort by: Date \| Relevance
Sangamo Biosciences (SGMO) gets $6.4 M from CIR... [Published Proactive Investors USA - 22 mins ago]
Sangamo BioSciences Receives $6.4M Strategic Pa... [Published Benzinga.com - 8 hours ago]
Sangamo BioSciences Receives $6.4 Million Strat... [Published ADVFN India - 8 hours ago]
Sangamo BioSciences Receives $6.4 Million Strat... [Published PR Newswire: General Business - 8 hours ago]
Sangamo BioSciences Presents Clinical Data Demo... [Published National AIDS Treatment Advocacy Project - May 23 2013]
Stocks in Focus (OSI Systems, Empresas ICA SA, ... [Published SBWire - May 21 2013]
Sangamo BioSciences Presents New Data From In V... [Published ADVFN UK - May 20 2013]
Sangamo BioSciences Presents New Data From In V... [Published TickerTech.com - May 20 2013]
CALIFORNIA: Oakland HIV/AIDS Housing the Focus ... [Published AEGIS - May 16 2013]
Genesee County Health Department Seeks Help at ... [Published AEGIS - May 16 2013]
CALIFORNIA: NorCal AIDS Cycle Opening and Closi... [Published AEGIS - May 16 2013]
Gilead Offers Response Data from Idelalisib; Sa... [Published BioMedReports - May 16 2013]
Healthcare Review: Sangamo Biosciences, MannKin... [Published BioMedReports - May 15 2013]
Sangamo Reports Zinc Finger Gene Therapy Leads ... [Published HIV and Hepatitis.com - May 15 2013]
SANGAMO BIOSCIENCES, INC.: Sangamo BioSciences ... [Published 4 Traders - May 15 2013]
UPDATE: Sangamo Highlights Encouraging Prelimin... [Published Benzinga.com - May 15 2013]
Sangamo BioSciences Presents Clinical Data Demo... [Published Street Insider - May 15 2013]
Sangamo BioSciences Presents Clinical Data Demo... [Published Stockwatch - May 15 2013]
Sangamo BioSciences Presents Clinical Data Demo... [Published TickerTech.com - May 15 2013]
Sangamo BioSciences Presents Clinical Data Demo... [Published PR Newswire: Health - May 15 2013]
Sangamo BioSciences' CEO Discusses Q1 2013 Resu... [Published Seeking Alpha - May 10 2013]
Actavis Confirms District Court Ruling In Gener... [Published BioMedReports - May 10 2013]
Sangamo BioSciences Announces Presentation at t... [Published Individual.com - May 09 2013]
Sangamo BioSciences Announces Presentation at t... [Published PR Newswire: Health - May 09 2013]
Sangamo BioSciences Reports First Quarter 2013 ... [Published Yahoo! Finance - May 08 2013]
Sangamo BioSciences Reports First Quarter 2013 ... [Published Barchart - May 08 2013]
SANGAMO BIOSCIENCES, INC.: Sangamo BioSciences ... [Published 4 Traders - May 01 2013]
Sangamo BioSciences Announces First Quarter 201... [Published Individual.com - May 01 2013]
Sangamo BioSciences Announces Presentation At T... [Published Barchart - Apr 24 2013]
Sangamo BioSciences Announces Presentation At T... [Published PR Newswire: General Business - Apr 24 2013]